Navigation Links
U.S. Gastroenterologists Have Increased Their TNF-alpha Inhibitor Use Since 2012, Especially for AbbVie's Humira, as a Result of Its Recent Approval in Ulcerative Colitis

BURLINGTON, Mass., Nov. 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that through examination of U.S. patient-level claims data, the TNF-alpha inhibitors drug class has seen growth in all three lines of therapy, particularly the second- and third-lines, for newly diagnosed ulcerative colitis (UC) patients.

The report entitled Key Findings from Treatment Algorithms in Ulcerative Colitis finds that Janssen's Remicade is the most prescribed biologic for recently treated UC patients, followed by AbbVie's Humira. Patient share for Humira has grown 41 percent over the past year under study, likely due to its FDA approval for use in UC in September 2012. Overall, the use of TNF-alpha inhibitors has increased by 17 percent since 2012.

The findings also reveal that Remicade is more often used as a first-line biologic and therefore had more continuing patients than Humira. However, since Humira is typically used as a later-line biologic, it draws more patients from adding/switching.

"Both Remicade and Humira have very high compliance and persistency rates, which is likely adding to the increased prescriptions," said Decision Resources Analyst Jen Dolga. "However, it is important to note that despite the growth in biologic use, oral aminosalicylates remain the most commonly prescribed drug class for both newly diagnosed and recently treated patients, indicating that a less intimidating side effect profile is still important to gastroenterologists."

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Local Gastroenterologists First in South Florida to Offer Fecal Transplant
2. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
3. Gastroenterologists Unlikely To Use Celltrion/Hospiras Infliximab Biosimilar Due To Lack Of Clinical Data In Inflammatory Bowel Disease
4. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
5. Study Published In Contraception Evaluates Medical Expenditures For Unintended Pregnancies And Potential Cost Impact Of Increased Use Of Long-Acting Reversible Contraception
6. Surgical Equipment Market to 2018 - Increased Access to Ambulatory Surgical Centers to Drive Outpatient Surgery Volumes
7. Unigene and Tarix Pharmaceuticals Report Highly Increased Oral Bioavailability of "Peptelligence-engineered" TXA127
8. Call for Submissions: ICAP Patent Brokerage Announces Expansion of Life Sciences Practice and Increased Buyer Interest in Related Intellectual Property
9. Global eClinical Trial Solutions Market to 2018 - Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies: MarketResearchReports.Biz
10. Artificial disc brings increased mobility and rapid recovery to patients suffering chronic neck pain in the Midwest
11. DePuy Settlement Funding And Transvaginal Mesh Capital Increased At Legal-Bay
Post Your Comments:
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
(Date:11/25/2015)... Nov. 25, 2015  ARKRAY USA ... to provide evidence demonstrating the accuracy of its blood ... on Insulin Resistance, Diabetes and Cardiovascular Disease in ... the Company,s GLUCOCARD ® 01 meter and the ... requirements. The ability to accurately measure glucose levels in ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... , ... Safe storage for contraceptive devices may not always be easy to ... and the other from Bradley Beach, New Jersey, there is an easy solution to ... to replace NuvaRings more often than necessary. As such, it affords peace of mind ...
(Date:11/27/2015)... ... November 28, 2015 , ... There is only one major question facing ... last year? , This question has not been an easy question to answer. Especially ... age and the younger workforce don’t share the same discipline around working long hours. ...
(Date:11/27/2015)... ... 27, 2015 , ... The rapid speed at which Americans ... more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming ... The forgotten part of this equation: 80 percent of medical care occurs in ...
(Date:11/27/2015)... ... 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that ... of their purchase of lice treatment product. In addition, customers will receive a complimentary ... spokesperson. “Finding lice is a sure way to ruin the holidays, so we encourage ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... will begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas ...
Breaking Medicine News(10 mins):